NCT01889173 - Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

March 31, 2014

Conditions

Healthy Adults

Interventions

DRUG

TNX-102 SL Tablets at 2.8 mg

1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

DRUG

TNX-102-B SL Tablets at 2.8 mg

1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

DRUG

TNX-102-C SL Tablets at 2.8 mg

1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

DRUG

Cyclobenzaprine tablets

1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water

Trial Locations (1)

PharmaNet, Inc., Québec

All Listed Sponsors

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY